November 12, 2015Open Access

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Objective determination of PD-L1 protein levels in NSCLC reveals heterogeneity within tumors and prominent interassay variability or discordance. This could be due to different antibody affinities, limited specificity, or distinct target epitopes. Efforts to determine the clinical value of these observations are under way.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

McLaughlin et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69d96ebcda3af5b1d08368a8 — DOI: https://doi.org/10.1001/jamaoncol.2015.3638

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).· 2014 · 64 citations
Tissue expression of PD-L1 mediates peripheral T cell tolerance· 2006 · 1,204 citations
Automated subcellular localization and quantification of protein expression in tissue microarrays· 2002 · 779 citations
A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.· 2013 · 191 citations

Authors

Joseph McLaughlin

Gang Han

Kurt A. Schalper

Journals

JAMA Oncology

Actions

Institutions

Yale University

Cleveland Clinic

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion